5 results on '"Montes-Garcia C"'
Search Results
2. Frailty and Depression in Late Life: A High-Risk Comorbidity With Distinctive Clinical Presentation and Poor Antidepressant Response.
- Author
-
Brown PJ, Ciarleglio A, Roose SP, Montes Garcia C, Chung S, Fernandes S, and Rutherford BR
- Subjects
- Aged, Antidepressive Agents therapeutic use, Comorbidity, Depression drug therapy, Depression epidemiology, Humans, Treatment Outcome, Depressive Disorder, Major complications, Depressive Disorder, Major drug therapy, Depressive Disorder, Major epidemiology, Frailty complications
- Abstract
Background: To investigate the longitudinal relationship between physical frailty, the clinical representation of accelerated biological aging, and antidepressant medication response in older adults with depressive illness., Methods: An 8-week randomized placebo-controlled trial (escitalopram or duloxetine) followed by 10 months of open antidepressant medication treatment (augmentation, switch strategies) was conducted in an outpatient research clinic. 121 adults aged 60 years or older with major depressive disorder (MDD) or persistent depressive disorder and a 24-item Hamilton Rating Scale for Depression (HRSD) ≥16 were enrolled. Primary measures assessed serially over 12 months include response (50% reduction from baseline HRSD score), remission (HRSD score <10), and frailty (non/intermediate frail [0-2 deficits] vs frail [≥3 deficits]); latent class analysis was used to classify longitudinal frailty trajectories., Results: A 2-class model best fit the data, identifying a consistently low frailty risk (63% of the sample) and consistently high frailty risk (37% of the sample) trajectory. Response and remission rates (ps ≤ .002) for adults in the high-risk frailty class were at least 21 percentage points worse than those in the low-risk class over 12 months. Furthermore, subsequent frailty was associated with previous frailty (ps ≤ .01) but not previous response or remission (ps ≥ .10)., Conclusions: Antidepressant medication is poorly effective for MDD occurring in the context of frailty in older adults. Furthermore, even when an antidepressant response is achieved, this response does little to improve their frailty. These data suggest that standard psychiatric assessment of depressed older adults should include frailty measures and that novel therapeutic strategies to address comorbid frailty and depression are needed., (© The Author(s) 2021. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
3. The COVID-19 Pandemic as a Traumatic Stressor: Mental Health Responses of Older Adults With Chronic PTSD.
- Author
-
Rutherford BR, Choi CJ, Chrisanthopolous M, Salzman C, Zhu C, Montes-Garcia C, Liu Y, Brown PJ, Yehuda R, Flory J, Neria Y, and Roose SP
- Subjects
- Adaptation, Psychological, Aged, Female, Humans, Life Change Events, Male, Mental Health, Middle Aged, New York epidemiology, Protective Factors, Psychiatric Status Rating Scales, Risk Factors, SARS-CoV-2, COVID-19 epidemiology, COVID-19 psychology, Depression diagnosis, Depression ethnology, Loneliness psychology, Resilience, Psychological, Stress Disorders, Post-Traumatic diagnosis, Stress Disorders, Post-Traumatic ethnology, Stress Disorders, Post-Traumatic physiopathology, Stress, Psychological diagnosis, Stress, Psychological etiology, Stress, Psychological prevention & control, Stress, Psychological psychology
- Abstract
Objective: Individuals with post-traumatic stress disorder (PTSD) who experience additional traumas or stressful life events may undergo symptomatic worsening, but no data exist on whether exposure to the COVID-19 pandemic in a high infection area worsens mental health among older adults with chronic PTSD., Methods: Seventy-six older adults (N = 46 with PTSD and N = 30 trauma-exposed comparison subjects [TE]) for whom prepandemic data were available were interviewed between April 1 and May 8, 2020 to quantify depressive (Hamilton Rating Scale for Depression [HRSD]) and PTSD symptom (Post-traumatic Stress Disorder Checklist [PCL-5]) levels. Group differences in baseline characteristics as well as pre-post pandemic symptom levels were examined, and participant characteristics were assessed as moderators of symptom change., Results: Compared to TEs, individuals with PTSD more often reported living alone and experiencing a physical illness (χ
2 = 5.1, df = 1, p = 0.02). PCL-5 scores among individuals with PTSD decreased during the COVID-19 pandemic by 7.1 points (t(69) = -3.5, p = 0.0008), whereas the TE group did not change significantly. Overall no significant differences in HRSD were found between groups, but a race or ethnicity variable was found to moderate HRSD symptom change. Non-black or Hispanic individuals with PTSD experienced significantly increased HRSD scores during the pandemic compared to black or Hispanic PTSD participants., Conclusion: The findings are indicative of complexity in the responses of older individuals with PTSD to further stressful life events as well as possibly unique aspects to the COVID-19 pandemic as a stressor. Sources of resilience may exist based on experience with prior traumas as well as increasing age promoting more adaptive coping styles., (Copyright © 2020 American Association for Geriatric Psychiatry. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
4. Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM): Study Design and Treatment Characteristics of the First 396 Participants Randomized.
- Author
-
Cristancho P, Lenard E, Lenze EJ, Miller JP, Brown PJ, Roose SP, Montes-Garcia C, Blumberger DM, Mulsant BH, Lavretsky H, Rollman BL, Reynolds CF 3rd, and Karp JF
- Subjects
- Aged, Aripiprazole, Bupropion, Humans, Lithium Compounds, Multicenter Studies as Topic, Nortriptyline, Pragmatic Clinical Trials as Topic, Treatment Outcome, Antidepressive Agents adverse effects, Antidepressive Agents therapeutic use, Depressive Disorder, Treatment-Resistant drug therapy
- Abstract
Objective: Evidence from clinical trials comparing effectiveness and safety of pharmacological strategies in older adults unresponsive to first-line antidepressants is limited. The study, Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM), tests three hypotheses concerning pharmacotherapy strategies for treatment-resistant late-life depression: 1) augmentation strategies will provide greater improvement than switching monotherapies; 2) augmentation strategies will have lower tolerability and more safety concerns than switching monotherapies; and 3) age will moderate the effectiveness and safety differences between treatment strategies. The authors describe the methodology, processes for stakeholder engagement, challenges, and lessons learned in the early phases of OPTIMUM., Methods: This pragmatic randomized clinical trial located in five North American regions will enroll 1,500 participants aged 60 years and older unresponsive to two or more antidepressant trials. The authors evaluate two strategies (medication augmentation versus switch) using four medications (aripiprazole, bupropion, lithium, and nortriptyline) via a stepwise, prespecified protocol. Primary outcomes include: 1) symptom remission (Montgomery Asberg Depression scale ≤10); 2) psychological well-being, comprising positive affect, general life satisfaction, and purpose; and 3) safety (rates of serious adverse events and prevalence of falls and fall-related injuries)., Results: To date, 396 participants have been randomized. The authors report on four challenges: 1) engagement and recruitment; 2) increasing polypharmacy in older adults, resulting in potentially hazardous scenarios; 3) reporting adverse events and procedure standardization across sites; and 4) dissemination of results., Conclusion: Solutions to these challenges, including early inclusion of stake holders, will inform future pragmatic studies in older adults with depression., (Copyright © 2019. Published by Elsevier Inc.)
- Published
- 2019
- Full Text
- View/download PDF
5. Treatment of FBSS Low Back Pain with a Novel Percutaneous DRG Wireless Stimulator: Pilot and Feasibility Study.
- Author
-
Weiner RL, Yeung A, Montes Garcia C, Tyler Perryman L, and Speck B
- Subjects
- Adult, Aged, Cohort Studies, Failed Back Surgery Syndrome diagnosis, Feasibility Studies, Female, Follow-Up Studies, Humans, Low Back Pain diagnosis, Male, Middle Aged, Pain Management instrumentation, Pain Measurement instrumentation, Pilot Projects, Prospective Studies, Treatment Outcome, Failed Back Surgery Syndrome therapy, Ganglia, Spinal physiology, Low Back Pain therapy, Pain Management methods, Pain Measurement methods, Spinal Cord Stimulation methods
- Abstract
Objectives: Test a miniaturized neurostimulator transforaminally placed at the dorsal root ganglion (DRG) and evaluate the device's safety and efficacy in treating failed back surgery syndrome (FBSS) low back pain., Design: Pilot, two-phase study., Subjects: Eleven subjects with chronic intractable neuropathic trunk and/or lower limbs pain were included., Methods: The system consisted of an implantable, miniaturized stimulator, provided by Stimwave Technologies (Freedom-4) and an external transmitter. Only one stimulator per subject was implanted unilaterally and transforaminally at L1 to L5 levels. During Phase 1 of the study, the stimulators were not anchored. In Phase 2, the stimulators were anchored. Subjects were treated during 45 days after which the stimulator was removed. Pain reduction, implant duration, and stimulator migration were registered., Results: Overall pain reduction was 59.9%, with only one device placed at one location, covering only a portion of the painful areas in the majority of the subjects. In Phase 1, the non-anchored stimulators migrated a mean of 8.80 mm and in Phase 2 a mean of 1.83 mm. Stimulator migration did not correlate with changes in pain relief. Mean time-to-implant duration was 10 minutes and no adverse events were reported during implant, follow-up period, or after explant., Conclusions: The pain reduction results indicate that the Freedom-4 spinal cord stimulation (SCS) Wireless System is a viable treatment of low back pain through stimulation of the DRG, and better overall pain reduction may be achieved by implanting multiple devices. With short percutaneous implant times and excellent safety profile, this new system may offer health cost savings., (© 2016 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.